### Radiomic signature accurately predicts the risk of 1 metastatic dissemination in late-stage non-small cell lung 2 3 cancer.

Agata Małgorzata Wilk<sup>1, 2, \$</sup>, Emilia Kozłowska<sup>1, \$,\*</sup>, Damian Borys<sup>1,3</sup>, Andrea 4 D'Amico<sup>3</sup>, Krzysztof Fujarewicz<sup>1</sup>, Izabela Gorczewska<sup>3</sup>, Iwona Debosz-5 Suwińska<sup>4</sup>, Rafał Suwiński<sup>5</sup>, Jarosław Śmieja<sup>1</sup>, Andrzej Swierniak<sup>1\*</sup>. 6

- <sup>1</sup>Department of Systems Biology and Engineering, Silesian University of Tech-7
- nology, Akademicka 16, 44-100, Gliwice, Poland; <sup>2</sup> Department of Biostatistics 8
- and Bioinformatics, Maria Sklodowska-Curie National Research Institute of On-9
- cology, Gliwice Branch, Wybrzeże Armii Krajowej 15, 44-102, Gliwice, Poland; 10
- <sup>3</sup> Department of Nuclear Medicine and Endocrine Oncology, PET Diagnostics 11
- Unit, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice 12
- Branch, Wybrzeże Armii Krajowej 15, 44-102, Gliwice, Poland; <sup>4</sup>Department of 13
- Radiotherapy, Maria Skłodowska-Curie National Research Institute of Oncology, 14
- Gliwice Branch, Wybrzeże Armii Krajowej 15, 44-102, Gliwice, Poland; <sup>5</sup>II-nd 15
- Radiotherapy and Chemotherapy Clinic and Teaching Hospital, Maria Skłodow-16
- ska-Curie National Research Institute of Oncology, Gliwice Branch, Wybrzeże 17
- 18 Armii Krajowej 15, 44-102, Gliwice, Poland.
- 19
- 20 \$ These authors contributed equally
- 21 \* Corresponding author

#### 22 **Corresponding authors:**

#### 23 **Prof. Andrzej Swierniak**

- 24 Department of Systems Biology and Engineering
- 25 Silesian University of Technology
- 26 Akademicka 16, 44-100 Gliwice, Poland
- 27 E-mail: andrzej.swierniak@polsl.pl
- 28 Phone number: 32 2372712
- 29

#### 30 Ph.D. Emilia Kozłowska

- 31 Department of Systems Biology and Engineering
- Silesian University of Technology 32
- 33 Akademicka 16, 44-100 Gliwice, Poland
- 34 E-mail: emilia.kozlowska@polsl.pl
- 35 Phone number: +48 32 2372119
- 36
- 37 Running title: Predicting the risk of metastasis in lung cancer.
- 38 Word count: 3824
- 39 Number of Figures: 6
- 40 Number of Tables: 1
- 41 42

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 43 **Author Contributions**

- 44 (I) Conception and design: EK, AS.
- 45 (II) Administrative support: AS, KF, JS.
- 46 (III) Provision of study materials or patients: IDS, RS, AD.
- (IV) Collection and assembly of data: IDS, DB, AD, IG, EK. 47
- 48 (V) Data analysis and interpretation: AMW, EK.
- 49 (VI) Manuscript writing: All authors.
- 50 (VII) Final approval of manuscript: All authors.

### Abstract 51

52

#### 53 **Background:**

- 54 Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, and the median
- 55 overall survival is approximately 2-3 years among patients with stage III disease. Furthermore,
- 56 it is one of the deadliest types of cancer globally due to non-specific symptoms and the lack of
- 57 a biomarker for early detection. The most important decision that clinicians need to make after 58
- a lung cancer diagnosis is the selection of a treatment schedule. This decision is based on,
- 59 among others factors, the risk of developing metastasis. 60

#### 61 Methods:

- A cohort of 115 NSCLC patients treated using chemotherapy and radiotherapy with curative 62 63 intent was retrospectively collated and included patients for whom positron emission tomogra-
- 64 phy/computed tomography (PET/CT) images, acquired before radiotherapy, were available.
- The PET/CT images were used to compute radiomic features extracted from a region of interest. 65
- 66 the primary tumor. Radiomic and clinical features were then classified to stratify the patients
- 67 into short and long time to metastasis, and regression analysis was used to predict the risk of
- 68 metastasis. 69

#### 70 **Results:**

- 71 Classification based on binarized metastasis-free survival (MFS) was applied with moderate
- 72 success. Indeed, an accuracy of 0.73 was obtained for the selection of features based on the
- 73 Wilcoxon test and logistic regression model. However, the Cox regression model for metastasis
- 74 risk prediction performed very well, with a concordance index (c-index) score equal to 0.84.
- 75

#### 76 **Conclusions:**

- 77 It is possible to accurately predict the risk of metastasis in NSCLC patients based on radiomic
- 78 features. The results demonstrate the potential use of features extracted from cancer imaging in 79 predicting the risk of metastasis.
- 80
- 81 Keywords: NSCLC, metastasis, Cox regression, classification, radiomics
- 82 83
- 84
- 85
- 86
- 87 88
- 89
- 90
- 91

#### Introduction 92

93 Lung cancer is one of the most frequently diagnosed cancer types worldwide, constituting over 94 11% of all cancer cases. With 2.2 million new diagnoses in 2020 alone, it was surpassed in 95 incidence only by breast cancer, making the lung the most prevalent cancer site in men (with 96 over 1.43 million diagnoses) and the third most prevalent in women after breast and colorectal 97 cancers, which had 0.77 million diagnoses (1). While tobacco smoking is recognized as the 98 primary cause of lung cancer, it can also be attributed to environmental factors such as air pol-99 lution, occupational exposure, and genetic predisposition (2-4). It is usually diagnosed at an 100 advanced stage due to non-specific early-stage symptoms, which is reflected in the very high 101 mortality rate. Indeed, the five-year survival rate for lung cancer does not exceed 20% (5–7), 102 thus, it is the leading cause of cancer-related mortality and is responsible for 18% of all deaths 103 from cancer (1).

104 Diagnosis of lung cancer involves medical imaging, including X-ray and positron emission to-105 mography/computed tomography (PET/CT), which allows for classification according to the 106 tumor node metastasis (TNM) staging system. Detected lesions are sampled by endobronchial 107 ultrasound (EBUS) guided bronchoscopy and undergo histopathological assessment. Manage-108 ment is stage-specific (7), with clinical guidelines divided into early-stage, locally advanced, 109 and metastatic cancer (8,9). In early-stage lung cancer, lobectomy is the preferred treatment 110 option. If the tumor is not initially resectable, neoadjuvant chemotherapy can be implemented to downgrade the tumor, which would eventually allow for surgery. For selected patients with 111 112 comorbidities, stereotactic radiotherapy (SABR) may also be considered. For locally advanced 113 cancer with lymph node involvement, platinum-based chemotherapy administered concurrently 114 or sequentially with radiotherapy is the most commonly used curative therapeutic option, and 115 it can be followed by maintenance immunotherapy. For advanced metastatic cancer, immune 116 checkpoint inhibitors, with or without chemotherapy, are a viable therapeutic option. As mo-117 lecular diagnostics becomes routinely available, targeted therapies aimed at epidermal growth 118 factor receptor (EGFR) (10), fibroblast growth factor receptor (FGFR) (11), anaplastic lym-119 phoma kinase (ALK) (12), or Kirsten rat sarcoma virus (KRAS) (13) are being used to treat

120 mutation carriers.

121 One of the main reasons for the high mortality seen in lung cancer is its invasiveness, and most

- 122 patients develop distant metastases. Unfortunately, metastatic tumors are often resistant to treat-
- 123 ment, which leads to much shorter survival times for these patients. Although the exact mech-
- 124 anisms of metastasis are still being investigated, it is known that cancer cells can spread by both
- 125 blood and lymphatic vessels (14). Lung cancer metastases are most frequently observed in the
- 126 brain, bones, liver, lung, and adrenal gland (15). Since the occurrence of distant metastasis is
- 127 the turning point in the course of the disease, it might be considered an important endpoint in
- 128 prognostic analysis, along with the standard endpoints. Furthermore, the ability to predict when
- 129 lung cancer will metastasize could guide clinical decision-making and may be used to indicate
- 130 the need for therapy intensification in high-risk patients.
- 131 The search for accurate prognostic biomarkers in lung cancer is hindered by its high heteroge-
- 132 neity and complexity. Nonetheless, clinical and molecular characteristics have shown some
- 133 promise in predicting metastasis. Metastasis-associated lung adenocarcinoma transcript 1 (MA-
- 134 LAT-1), a long non-coding ribonucleic acid (RNA), was demonstrated to be significantly asso-
- 135 ciated with metastasis in non-small cell lung cancer (NSCLC) (16). Meanwhile, cancer antigen
- 136 125 (CA125) and neuron-specific enolase (NSE) were found to be indicative of liver metastasis
- 137 (17). NSE, histological type, number of metastatic lymph nodes, and tumor grade were used to

medRxiv preprint doi: https://doi.org/10.1101/2023.01.31.23285230; this version posted February 1, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- construct a nomogram for use in brain metastasis prediction (18). Vimentin expression was also
   identified as a potential predictor of brain metastasis in *EGFR*-mutant NSCLC patients (19).
- 140 Recently, medical imaging has gained attention as an alternative source of biomarkers (20–22).
- 141 It has distinct advantages over molecular markers in that it is non-invasive, requires no addi-
- 142 tional assays, and utilizes information acquired during a routine diagnostic procedure. As such,
- imaging biomarkers are also the fastest to obtain, making them perfect for therapy planning.
- 144 Two main strategies can be used to acquire biomarkers. The first is to directly analyze raw
- 145 images. Another solution is radiomics, in which segmented images are subjected to feature ex-146 traction. This method provides numerical variables that describe the shape and texture of the
- region of interest (ROI), which can then be used in statistical or machine-learning models.
- region of interest (ROI), which can then be used in statistical or machine-learning model
- 148 The radiomics-based approach has been successfully applied for different endpoints in lung
- 149 cancer, including overall survival (OS) and progression-free survival (PFS) (23). It has also
- shown promising results for the prediction of distant metastases. Coroller et al. (24) selected a
- radiomic signature based on CT images to predict distant metastasis in lung adenocarcinoma.
- Wu et al. constructed and validated a Cox proportional hazards model using 18F-fluorodeoxy-
- glucose PET (<sup>18</sup>F-FDG PET) imaging to predict freedom of distant metastasis in early-stage
   NSCLC patients (25). Fave et al. (26) demonstrated that adding pre-treatment radiomic features
- 154 NSCLC patients (25). Fave et al. (26) demonstrated that adding pre-treatment radiomic features 155 extracted from CT images could improve the ability of clinical prognostic models to predict
- distant metastasis (26). Meanwhile, Dou et al. (27) focused on locally advanced lung adenocar-
- cinoma and investigated radiomic features from the primary tumor and peritumoral region (27).
- 158 In this study, 115 NSCLC patients with various histological subtypes were retrospectively an-
- 159 alyzed. The prognostic value of standard clinical features, and radiomic features extracted from
- 160 PET/CT images acquired for radiotherapy planning, were evaluated by determining if they
- 161 could be used to predict time to distant metastasis. To answer this question, machine learning
- 162 models were constructed for continuous and categorical metastasis-free survival (MFS) predic-
- 163 tion.
- 164

# 165 Materials and Methods

## 166 Study design

- A cohort of NSCLC patients was collated to investigate if PET/CT imaging routinely performed for radiotherapy planning could help in planning the future treatment strategy, with a focus on predicting the risk and time of relapse with distant metastases. MFS was defined as the time elapsed between diagnosis and the detection of distant metastasis or the time of death/last fol-
- 171 low-up if distant metastases did not emerge. In addition, classification algorithms were used to
- 172 predict if MFS would be short or long.
- 173 As the prediction of metastasis risk was the focus of the study, the primary lung cancer tumor
- was the ROI. Using the available PET/CT scans, radiomic features were extracted from the ROIand assessed.
- 176 The specific clinical question considered in this work was whether or not a radiomic signature
- could be extracted that would help discriminate between a primary tumor that has the potential
- 178 to metastasize early from one that metastasizes late or not at all.

#### **Study population** 179

Data were collected retrospectively at the Maria Sklodowska-Curie National Research Institute 180 181 of Oncology, Gliwice Branch (NRIO). The cohort consisted of 115 patients with NSCLC who 182 were treated with curative intent at the Institute between 2009 and 2017. All patients in the 183 cohort had been treated with a combination of chemotherapy and radiotherapy. Most of the 184 patients received a platinum-based doublet with vinorelbine. Patients received between one and 185 six cycles (median four), followed by radiotherapy (RT) with a total dose between 60 and 70 186 Gray (Gy) in two Gy fractions. The study was approved by the Local Bioethical Committee of the NRIO in accordance with national regulations. Formal written consent was obtained from 187 188 all participants of the study. The clinical data were anonymized before the computational anal-

- 189 ysis.
- 190 All patients underwent PET/CT imaging for radiotherapy planning. Only patients with non-
- 191 detectable distant tumors at the onset of treatment were assessed. However, most patients had
- 192 locally disseminated tumors to the lymph nodes, as they were diagnosed late due to non-specific
- 193 symptoms.

194 In the cohort, 72% of patients were males, and 28% were female. This is consistent with popu-

195 lation data showing that most lung cancer patients are male. The median age of patients in the

196 cohort was 61 years, and over half of the patients had tumors located in the left lung. The most

197 prevalent cancer subtype was squamous cell carcinoma, which constituted two-thirds of all

- 198 cases, followed by large cell carcinoma (24.3%) and adenocarcinoma (7.0%). Detailed charac-
- 199 teristics of the cohort are presented in Table 1.
- 200 The median time-to-metastasis was 2.77 years, with a secondary tumor observed most fre-201 quently in the second lung, brain, bones, and liver.
- 202

#### Positron emission tomography/computed tomography data acquisition and 203 segmentation 204

The PET/CT images were acquired at the NRIO using Philips GeminiGXL 16 (Philips, Am-205 206 sterdam, Netherlands) (24 patients) and Siemens Biograph mCT 131 (Siemens AG, Munich, 207 Germany) (88 patients) PET/CT scanners. For each patient, the ROI was contoured by the same 208 experienced nuclear medicine specialist using Medical Image Merge (MIM) 7.0.1 software and 209 the PET Edge<sup>TM</sup> tool (both MIM Software Inc., OH, USA).

#### 210 **Extraction of radiomic features**

211 Feature extraction was performed with PyRadiomics version 3.0.1, a Python package designed 212 to increase the reproducibility of radiomic studies (28). Using the PET dataset, 105 standard 213 features were calculated. Radiomic features belong to one of three classes, including first-order 214 statistics such as energy, entropy, and minimum, as well as shape features such as volume, 215 surface area, and sphericity, and texture features including Gray Level Co-occurrence Matrix 216 (GLCM), Gray Level Dependence Matrix (GLDM), Gray Level Run Length Matrix (GLRLM), 217 Gray Level Size Zone Matrix (GLSZM), and Neighboring-Gray Tone Difference Matrix 218 (NGTDM).

#### Metastasis-free survival categorization 219

220 For the classification, a threshold of one year was used to create two classes, which included 221 patients with MFS below and over this threshold. Due to the presence of censored observations 222 (in the cohort this primarily signified the patient's death), such stratification divided patients 223 into a group who suffered either metastasis or death within a year (66 patients), and those who 224 did not (49 patients). To create subgroups that were more related to the research question, the 225 binary MFS was defined as "short" if the patient developed metastasis within a year (25 pa-226 tients) and "long" if the patient developed metastasis or was censored after longer than a year 227 (49 patients).

#### 228 **Statistical analysis**

229 Statistical analysis was performed using the R environment (version 4.1.3). For survival analy-

230 sis, survival (version 3.2-13) was used, caret (version 6.0.93) and RandomForest (version 4.7-

231 1.1) were used for classification, and randomForestSRC (version 3.1.1) was used to perform

232 random survival forest. A heatmap of the radiomic features was created with ComplexHeatmap

233 (version 2.10.0).

234 Filtering of the radiomic features was applied based on the Pearson correlation coefficient to

235 avoid redundancy, with a cutoff threshold equal to 0.9 (see Supplementary Table 1). Since the

236 PET images were acquired using two scanners, principal component analysis was applied to

- 237 determine if there was any grouping of samples due to the scanner used (see Supplementary
- 238 Figure 1).

239 The clinical and radiomic features with potential for event-free survival (EFS) and MFS prediction were assessed (see Supplementary Table 2). In addition, differences in the values of 240 241 radiomic and clinical features between 'short' and 'long' MFS patient subgroups were investi-

242 gated statistically. Fisher's exact test was performed for categorical variables, while the Mann-

243 Whitney U test was used for continuous variables (see Supplementary Table 3). A log-rank test

244 was also conducted for both categorical and continuous features (see Supplementary Table 4).

245 As the log-rank test assesses if there is a significant difference between two or more survival

246 curves, continuous features were binarized with respect to the median value.

#### **Cross-validation** 247

The value of any type of predictive model lies in its applicability to unknown data, and not just 248 249 its ability to fit the training data. Cross-validation enables evaluation of the model's ability to 250 generalize by removing part of the data from the cohort and applying them in the estimation of 251 model performance. In addition, data partitioning at the beginning of each iteration prevents 252 information leakage.

253 For a more consistent comparison between the regression and classification results, modified

254 k-fold data partitioning was applied. Firstly, the data was ordered according to (continuous)

255 MFS values. Then, the observations were assigned consecutive numbers, from one to five,

256 which were used as cross-validation folds. Such partitioning ensures proper stratification of

257 both continuous and binarized MFS.

#### **Classification algorithms** 258

259 The observed relationships between binary MFS and binary EFS and extracted features (both 260 clinical radiomic) were verified by employing classification models. Firstly, three main feature 261 selection methods were applied, including Student's t-test, Wilcoxon test, and a mutual information test. To investigate the impact of a varying number of features on classification quality, 262 263 between 1 and 10 features were tested. Since only the mutual information method handles both 264 categorical and continuous variables, a hybrid selection was used for the other two methods by 265 applying the main method for continuous variables and Fisher's exact test for categorical variables. The categorical variables that passed the significance threshold equal to 0.1 were added 266 267 to the model.

268 The following classification methods were tested: K Nearest Neighbor (KNN) with different K 269 values (for clarity, only the best one, K=5, is presented), random forest, support vector machines 270 (SVM) with linear and radial kernels, and logistic regression (LogReg). Considering the inconsistent orders of magnitude for radiomic features, a z-score transformation was used to scale 271 the data. In each k-fold iteration, the scaling parameters (mean and standard deviation) were 272 273 determined from the training set and applied to both the training and test sets. Classification 274 accuracy was then used to assess model performance.

#### **Regression algorithms** 275

276 For the prediction of continuous MFS, Cox proportional hazards regression (using survival R 277 package) and random survival forest (using randomForestSRC R package) were applied. Vari-278 able selection was performed based on univariate analysis, with the Harrell Concordance index 279 (C-index) adopted as a ranking metric. The model performance was validated using the k-fold 280 partitioning described above. Again, models containing between 1 and 10 features were tested.

281

#### **Radiomic-based risk score** 282

283 Although cross-validation facilitates the estimation of prediction quality, the results and selected features can be different in each iteration due to subsampling. Therefore, all selections 284 285 were repeated on the entire dataset to obtain conclusive feature rankings. To demonstrate the 286 validity of the obtained signature, the Cox model was chosen, which is the classic approach to survival data analysis with known interpretation. The patients were then divided into high-risk 287 288 and low-risk groups based on the calculated median risk score, and MFS was compared using 289 Kaplan-Meier curves.

#### Results 290

#### **Patient characteristics** 291

292 The cohort included only NSCLC patients, as it is the most common type of lung cancer. Most 293 patients (67%) had squamous histopathological subtypes, and almost two-thirds had an ad-

294 vanced stage of the primary tumor (T3 or T4). In total, 37 patients eventually developed distant

295 metastases. Figure 2A shows a Kaplan-Meier plot for MFS probability in the entire patient

296 cohort.

297 None of the clinical features of the cohort were informative in relation to the time to metastasis 298 onset (Supplementary Table 2). This means that clinicians are unable to predict if a particular 299 patient will develop metastatic cancer, based only on clinical variables at diagnosis. On the

300 other hand, 34 radiomic features were statistically significant against continuous MFS, 36 fea-

- 301 tures against the binarized MFS, and 18 against EFS.
- 302

#### 303 Integration of clinical and radiomic data

- 304 High correlations were observed between the radiomic features, which resulted in only 65 of 305 105 features passing the initial correlation filtering. The highest redundancy was found for the
- 306 first-order features (6 out of were18 kept) and the lowest for the GLSZM features (15 out of 16
- 307 were kept) (see Supplementary Table 1).
- 308 Correlations between radiomic and clinical features were mostly low, signifying that both da-309 tasets carried independent information. Also, the hierarchical clustering of radiomic features
- 310 did not correspond to any discernible grouping of clinical features (see Figure 2).
- Figure 2B shows the normalized z-score values of radiomic features for each patient. The pa-311
- 312 tients were divided into short and long EFS groups. As can be seen from the results, the hierar-
- 313 chical clustering correctly divided patients into these two groups. Furthermore, it was observed
- 314 that the radiomic feature spectrum varied between patients with short and long EFS. This
- 315 demonstrates that there is potential for the use of radiomic features in predicting EFS.

#### 316 Classification of advanced non-small cell lung cancer

317 As expected, no clinical features were selected by the models. The feature rankings obtained 318 for EFS and MFS prediction differed, which aligns with the different interpretations of these 319 endpoints. While the rankings varied with respect to feature selection and classification meth-320 ods, there was some consistency among the top features. Indeed, TotalEnergy, ZoneEntropy, 321 and RootMeanSquared favored EFS prediction, while Variance, TotalEnergy, RunLength-322 NonUniformity (GLRLM), SizeZoneNonUniformityNormalized, and Maximum2DDiameter-323 Column favored MFS prediction.

- 324 The highest accuracy for EFS prediction (approx. 0.65) was achieved using the SVM classifier 325 with linear kernels for the mutual information selection of eight features. The highest accuracy 326 for MFS prediction (approx. 0.73) was achieved using the LogReg classifier for the five features 327 selected using the Wilcoxon test. Due to the imbalanced classes, with "long" (treated as the 328 negative class) being the predominant group, the models for MFS tended to yield high speci-329 ficity and relatively low sensitivity. Most models performed better for a small number of fea-330 tures.

#### 331 Prediction of risk of metastasis

For regression-based models, the tendency was similar, with the highest predictive ability ob-332

- 333 served for a small number of features. The highest median C-index across folds was reached
- 334 for two features (GLRLM and NGTDM Business) in Cox regression and one feature (shapeMi-
- 335 norAxisLength) in the random survival forest.

- 336 The mean C-index for the best set of features using Cox regression was 0.84, whereas the C-
- index for the random survival forest was 0.8. The inclusion of more features in the model re-337 338 sulted in a loss of prediction quality due to overfitting. No clinical features were selected for
- 339 the best models, which is consistent with the preliminary patient cohort analysis.

340 Feature selection on the entire dataset revealed that the two top features for Cox regression, 341 SmallAreaLowGrayLevelEmphasis (GLSZM) and GLRLM, also held high-ranking positions

- 342 in the classification approach. Therefore, the Cox model was constructed using those two fea-
- 343 tures. The high-risk and low-risk groups (Figure 6) had significantly different MFS, with the
- 344 log-rank test P<0.001.
- 345

### Discussion 346

347 Lung cancer is the leading cause of cancer-related death worldwide, claiming over 1.7 million

- 348 lives yearly. It is characterized by high invasiveness, and the occurrence of distant spread sig-349 nificantly influences survival and treatment options. This necessitates the search for prognostic
- 350 biomarkers that could help determine the time to metastasis onset. With the rapid development
- 351 of the radiomics field, researchers have turned to medical imaging, which is routinely per-
- 352 formed and non-invasive, as a source of information that could shed some light on the tumor
- 353 dissemination process and aid clinicians in therapy planning.

354 A cohort of NSCLC patients with different subtypes and stages of the disease was collated. It 355 was concluded that the standard clinical data available for the patients, except for higher meta-

356 static potential exhibited by the squamous subtype, were largely uninformative regarding me-

357 tastasis occurrence. To assess the potential of radiomics for MFS prediction, we extracted 105

358 radiomic features from PET/CT scans, using the primary tumor as the ROI. Regression and

- 359 machine learning methods were then used to select radiomic signatures that could predict the
- 360 risk of metastasis and achieved a C-index of 0.84 for the Cox proportional hazards model and 361 0.8 for the random survival forest, and an accuracy of 0.72 for the KNN classifier. These results
- 362 confirm that medical images contain information that could be successfully applied to MFS
- 363 prediction.

364 Several studies have shown the potential of radiomic features in predicting distant metastasis 365 in lung cancer, with most of them focusing on either a particular subtype or stage. Coroller et 366 al. (24) investigated radiomic features extracted from CT images for predicting distant metas-367 tasis in lung adenocarcinoma, which had a C-index of 0.61 on an independent validation set. 368 Fave et al. (26) demonstrated that combining pre-treatment radiomic features with clinical in-369 formation improved the ability of prognostic models to predict distant metastasis in stage III 370 NSCLC patients, reporting a C-index of 0.63 (24). Wu et al. used features extracted from PET 371 images to predict the freedom of distant metastasis, with a high C-index of 0.71 in independent 372 validation (25). However, this work only focused on early-stage lung cancer. Dou et al. (27) 373 presented an interesting approach, extracting features from both the tumor and tumor rim and 374 achieving a C-index of 0.64 in a cohort of patients with locally advanced lung adenocarcinoma 375 (27). In the current work, significantly better model quality was achieved in a cohort including 376 patients with varying subtypes (squamous cell carcinoma, adenocarcinoma, large cell carci-377 noma) and stages.

378 While a regression approach, such as a Cox proportional hazards model, is typically used for 379 survival-type analysis, the risk score it yields does not directly translate to the time of event

- 380 occurrence. The C-index only compares pairs of observations, resulting in a global assessment
- 381 of whether a higher risk is related to a shorter time-to-event. Therefore, classification was also
- 382 performed and achieved an accuracy of 0.72 in cross-validation.

After testing several methods and approaches to variable selection, it was observed that similar predictive ability could be achieved for different feature sets, which indicates that even unrelated radiomic features carry equivalent information. Interestingly, the quality dropped drastically with increased feature numbers in all models. This suggests that features with high predictive potential perform much worse when combined than when used in isolation, and empha-

- 388 sizes the importance of selecting algorithms that are sensitive to feature interactions.
- Certain variables retained high positions across different selections. These included GLRLM,
   NGTDM Strength, and NGTDM Business. This demonstrates that these radiomic features are
- important for predicting if and when metastasis will occur in a lung cancer patient.

392 This analysis was not without limitations. While the study design ensured all images were con-

toured by one expert, which prevented bias, this did not allow for an assessment of the repro-

ducibility of radiomic feature extraction. In addition, plans are in place to collect an independent

- 395 patient cohort to validate the signature. Future work will also investigate tumor growth and396 dissemination dynamics, to achieve more clinically meaningful predictions.
- dissemination dynamics, to achieve more clinically meaningful predictions.
- 397

## 398 Conclusions

399 Based on a cohort comprised of 115 NSCLC patients, clinical features routinely collected dur-

ing diagnostic procedures are not sufficient for the prediction of the risk of metastasis. Medical
 images (PET/CT scans) were investigated as a potential source of prognostic markers by as-

401 mages (FET/CT scans) were investigated as a potential source of prognostic markers by as-402 sessing radiomic features in various classes of predictive models. A model based on two texture

features (GLSZM and GLRLM) was constructed, which divided the patient cohort into low-

404 risk and high-risk groups that significantly differed in MFS. The findings of this study have the

405 potential to help clinicians make adjustments to therapy and create a rational basis for the in-

406 tensification of systemic treatment in high-risk lung cancer patients.

407

# 408 Acknowledgments

409 This work was supported by the Polish National Science Centre, Grant Number: UMO-410 2020/37/B/ST6/01959, and Silesian University of Technology statutory research funds. Calcu-411 lations were performed on the Ziemowit computer cluster in the Laboratory of Bioinformatics 412 and Computational Biology, created in the EU Innovative Economy Programme 413 POIG.02.01.00-00-166/08 and expanded in the POIG.02.03.01-00-040/13 project. Data analy-414 sis was partially carried out using the Biotest Platform developed within project PBS3/B3/32/2015, which was financed by the Polish National Centre of Research and Devel-415 416 opment (NCBiR). This work was carried out in part by the Silesian University of Technology 417 internal research funding (A.M.W., E.K., D.B., K.F., J.S., and A.S.). The founders have no role 418 in designing the study and writing the manuscript.

419

## 420 Footnotes

### 421 **Reporting checklist**

422 The authors have completed the "Prediction Model Development and Validation" reporting423 checklist.

### 424 Data Sharing Statement

425 The authors submitted a data-sharing statement along with the manuscript.

### 426 **Conflict of interest**

427 The authors declare no competing interests.

### 428 Ethical statement

429 The authors are accountable for all aspects of the work and will ensure that questions related to

- 430 the accuracy or integrity of any part of the work are appropriately investigated and resolved.
- The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).
  The study was approved by the institutional board of Maria Skłodowska-Curie National Re-
- 432 The study was approved by the institutional board of Maria Skiodowska-Curie National Re-433 search Institute of Oncology (Gliwice Branch), and individual consent for this retrospective
- 435 search institute of Oncology (Onwice Branch), and individual consent for this retrospective 434 analysis was waived
- 434 analysis was waived.

435

436

437

438

## 439 **References**

- Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer
   statistics for the year 2020: An overview. Int J Cancer [Internet]. 2021 Aug 15 [cited
   2022 Nov 27];149(4):778–89. Available from: https://pub-
- 443 med.ncbi.nlm.nih.gov/33818764/
- Alberg AJ, Samet JM. Epidemiology of lung cancer [Internet]. Vol. 123, Chest. Chest;
  2003 [cited 2022 Nov 27]. p. 21S-49S. Available from: https://pubmed.ncbi.nlm.nih.gov/12527563/
- dela Cruz CS, Tanoue LT, Matthay RA. Lung Cancer: Epidemiology, Etiology, and
  Prevention. Vol. 32, Clinics in Chest Medicine. 2011. p. 605–44.
- 449 4. Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer [Internet].
  450 Vol. 85, Annals of Global Health. Ann Glob Health; 2019 [cited 2022 Nov 27]. Availa-451 ble from: https://pubmed.ncbi.nlm.nih.gov/30741509/
- 452 5. Lu T, Yang X, Huang Y, Zhao M, Li M, Ma K, et al. Trends in the incidence, treat-
- 453 ment, and survival of patients with lung cancer in the last four decades. Cancer Manag
- 454
   Res [Internet]. 2019 [cited 2022 Nov 27];11:943–53. Available from: https://pub 

   455
   med.ncbi.nlm.nih.gov/30718965/

- 456 6. Torre LA, Siegel RL, Jemal A. Lung Cancer Statistics. Adv Exp Med Biol [Internet]. 457 2016 [cited 2022 Nov 27];893:1-19. Available from: https://pub-458 med.ncbi.nlm.nih.gov/26667336/ 459 Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: Epi-7. 460 demiology, risk factors, treatment, and survivorship. In: Mayo Clinic Proceedings [In-461 ternet]. Elsevier Ltd; 2008 [cited 2021 Mar 20]. p. 584–94. Available from: 462 http://www.mayoclinicproceedings.org/article/S0025619611607350/fulltext Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic 463 8. 464 non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol [Internet]. 2018 Oct 1 [cited 2022 Nov 27];29(Suppl 465 466 4):iv192–237. Available from: https://pubmed.ncbi.nlm.nih.gov/30285222/ Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early 467 9. 468 and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice 469 Guidelines for diagnosis, treatment and follow-up. Annals of Oncology [Internet]. 2017 470 [cited 2022 Nov 27];28(suppl 4):iv1-21. Available from: https://pub-471 med.ncbi.nlm.nih.gov/28881918/ 472 Le T, Gerber DE. Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They 10. 473 Best Used? Cancers (Basel) [Internet]. 2019 Mar 1 [cited 2023 Jan 19];11(3). Available from: https://pubmed.ncbi.nlm.nih.gov/30875928/ 474 475 Zhou Z, Liu Z, Ou Q, Wu X, Wang X, Shao Y, et al. Targeting FGFR in non-small cell 11. 476 lung cancer: implications from the landscape of clinically actionable aberrations of 477 FGFR kinases. Cancer Biol Med [Internet]. 2021 May 5 [cited 2023 Jan 19];18(2):490. 478 Available from: /pmc/articles/PMC8185861/ 479 Yuan M, Huang LL, Chen JH, Wu J, Xu Q. The emerging treatment landscape of tar-12. 480 geted therapy in non-small-cell lung cancer. Signal Transduct Target Ther [Internet]. 481 2019 [cited 2022 Nov 27];4(1). Available from: https://pub-482 med.ncbi.nlm.nih.gov/31871778/ 483 Salgia R, Pharaon R, Mambetsariev I, Nam A, Sattler M. The improbable targeted ther-13. 484 apy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). Cell Rep 485 Med [Internet]. 2021 Jan 19 [cited 2022 Nov 27];2(1). Available from: https://pub-486 med.ncbi.nlm.nih.gov/33521700/ 487 14. Popper HH. Progression and metastasis of lung cancer. Cancer Metastasis Rev [Inter-488 net]. 2016 Mar 1 [cited 2022 Nov 27];35(1):75-91. Available from: https://pub-489 med.ncbi.nlm.nih.gov/27018053/ 490 15. Riihimäki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, et al. 491 Metastatic sites and survival in lung cancer. Lung Cancer [Internet]. 2014 Oct 1 [cited 492 2022 Nov 27];86(1):78-84. Available from: https://pub-493 med.ncbi.nlm.nih.gov/25130083/ 494 Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epi-16. 495 demiology, risk factors, treatment, and survivorship. Mayo Clin Proc [Internet]. 2008 496 [cited 2022 Nov 27];83(5):584–94. Available from: https://pub-497 med.ncbi.nlm.nih.gov/18452692/ 498 Wang CF, Peng SJ, Liu RQ, Yu YJ, Ge QM, Liang R bin, et al. The Combination of 17. 499 CA125 and NSE Is Useful for Predicting Liver Metastasis of Lung Cancer. Dis Mark-500 ers [Internet]. 2020 [cited 2022 Nov 27];2020. Available from: https://pub-501 med.ncbi.nlm.nih.gov/33376560/ 502 18. Zhang F, Zheng W, Ying L, Wu J, Wu S, Ma S, et al. A Nomogram to Predict Brain 503 Metastases of Resected Non-Small Cell Lung Cancer Patients. Ann Surg Oncol [Internet]. 2016 Sep 1 [cited 2022 Nov 27];23(9):3033-9. Available from: https://pub-504 505 med.ncbi.nlm.nih.gov/27090794/

medRxiv preprint doi: https://doi.org/10.1101/2023.01.31.23285230; this version posted February 1, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Teocharoen R, Ruangritchankul K, Vinayanuwattikun C, Sriuranpong V, Sitthideatphaiboon P. Vimentin expression status is a potential biomarker for brain metastasis
development in EGFR-mutant NSCLC patients. Transl Lung Cancer Res [Internet].
2021 Feb 1 [cited 2022 Nov 27];10(2):790–801. Available from: https://pubmed.ncbi.nlm.nih.gov/33718022/

- Lee G, Lee HY, Park H, Schiebler ML, van Beek EJR, Ohno Y, et al. Radiomics and its emerging role in lung cancer research, imaging biomarkers and clinical management: State of the art. Eur J Radiol [Internet]. 2017 Jan 1 [cited 2022 Nov 27];86:297– 307. Available from: https://pubmed.ncbi.nlm.nih.gov/27638103/
- Avanzo M, Stancanello J, Pirrone G, Sartor G. Radiomics and deep learning in lung
  cancer. Strahlenther Onkol [Internet]. 2020 Oct 1 [cited 2022 Nov 27];196(10):879–87.
  Available from: https://pubmed.ncbi.nlm.nih.gov/32367456/
- 518 22. Stieb S, McDonald B, Gronberg M, Engeseth GM, He R, Fuller CD. Imaging for Tar519 get Delineation and Treatment Planning in Radiation Oncology: Current and Emerging
  520 Techniques. Hematol Oncol Clin North Am [Internet]. 2019 Dec 1 [cited 2023 Jan
  521 19];33(6):963-75. Available from: https://pubmed.ncbi.nlm.nih.gov/31668214/
- Zhang Y, Oikonomou A, Wong A, Haider MA, Khalvati F. Radiomics-based Prognosis
  Analysis for Non-Small Cell Lung Cancer. Sci Rep [Internet]. 2017 Apr 18 [cited 2022
  Nov 27];7. Available from: https://pubmed.ncbi.nlm.nih.gov/28418006/
- 525 24. Coroller TP, Grossmann P, Hou Y, Rios Velazquez E, Leijenaar RTH, Hermann G, et
  526 al. CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma.
  527 Radiother Oncol [Internet]. 2015 Mar 1 [cited 2022 Nov 27];114(3):345–50. Available
  528 from: https://pubmed.ncbi.nlm.nih.gov/25746350/
- 529 25. Wu J, Aguilera T, Shultz D, Gudur M, Rubin DL, Loo BW, et al. Early-Stage Non530 Small Cell Lung Cancer: Quantitative Imaging Characteristics of (18)F Fluorodeoxy531 glucose PET/CT Allow Prediction of Distant Metastasis. Radiology [Internet]. 2016
  532 Oct 1 [cited 2022 Nov 27];281(1):270–8. Available from: https://pub533 med.ncbi.nlm.nih.gov/27046074/
- 534 26. Fave X, Zhang L, Yang J, MacKin D, Balter P, Gomez D, et al. Delta-radiomics fea535 tures for the prediction of patient outcomes in non-small cell lung cancer. Sci Rep [In536 ternet]. 2017 Dec 1 [cited 2022 Nov 27];7(1). Available from: https://pub537 med.ncbi.nlm.nih.gov/28373718/
- Dou TH, Coroller TP, van Griethuysen JJM, Mak RH, Aerts HJWL. Peritumoral radiomics features predict distant metastasis in locally advanced NSCLC. PLoS One [Internet]. 2018 Nov 1 [cited 2022 Nov 27];13(11). Available from: https://pubmed.ncbi.nlm.nih.gov/30388114/
- van Griethuysen JJM, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V, et al.
  Computational radiomics system to decode the radiographic phenotype. Cancer Res
  [Internet]. 2017 Nov 1 [cited 2023 Jan 19];77(21):e104–7. Available from: https://pubmed.ncbi.nlm.nih.gov/29092951/
- 547 **Tables**

546

548 **Table 1.** Patient characteristics. For continuous variables, median and quartiles are listed.

		N = 115
Sex	Male	83 (72.2%)
	Female	32 (27.8%)

Age		61 (57-67)
Histopathology	Squamous	77 (67.0%)
	Adenocarcinoma	8 (7.0%)
	Large cell	28 (24.3%)
	Other	2 (1.7%)
	Left	65 (56.5%)
Location	Right	50 (43.5%)
Т	1	4 (3.5%)
	2	37 (32.2%)
	3	37 (32.2%)
	4	37 (32.2%)
Ν	0	19 (16.5%)
	1	6 (5.2%)
	2	83 (72.2%)
	3	7 (6.1%)
Μ	0	115 (100%)
	1	0 (0%)
Zubrod score	0	34 (29.6%)
	1	80 (69.6%)
	2	1 (0.9%)

## 565 Figures



566

567 **Figure 1:** Project workflow. Positron emission tomography/computed tomography (PET/CT) 568 images were acquired and radiomic features were extracted from regions of interest (ROI). In-

569 tegration of clinical and radiomic data led to the prediction of short-term and long-term metas-

570 tasis-free survival (MFS) and the risk of metastasis. The output from the workflow was a radi-

571 omic signature, which could be used for the prediction of metastasis risk in newly diagnosed

572 NSCLC patients being treated with platinum-based chemotherapy.





573

574 Figure 2: The integration of clinical and radiomic data. A. Kaplan-Meier plot of metastasis-575 free survival (MFS) for the entire population. B. Integration of clinical and radiomic data. Pa-576 tients were split by the binary event-free survival (EFS).





577

578 Figure 3: Metastasis-free survival (MFS) prediction using the classification approach. Top 579 row: Wilcoxon test; middle row: Student's t-test; bottom row: mutual information test. Left column: feature selection in a 5-fold cross-validation. Features were ranked according to the -580 log10(p-value) for the Wilcoxon test and Student's t-test selections, and mutual information 581 582 score for mutual information selection. Black dots indicate the median value across folds, green dots indicate the lowest value across folds, and red dots indicate the highest value. Right col-583 584 umn: classification results for the test set in a 5-fold cross-validation for different models, de-585 pending on the number of features.





### 586

587 Figure 4: Event-free survival (EFS) prediction using the classification approach. Top row: Wil-588 coxon test; middle row: Student's t-test; bottom row: mutual information. Left column: feature 589 selection in a 5-fold cross-validation. Features are ranked according to the -log10(p-value) for 590 the Wilcoxon test and Student's t-test selections, and mutual information score for mutual in-591 formation selection. Black dots indicate the median value across folds, green dots indicate the 592 lowest value across folds, and red dots indicate the highest value across folds. Right column: 593 classification results for the test set in a 5-fold cross-validation for different models, depending 594 on the number of features.



595

596 Figure 5: Metastasis-free survival (MFS) prediction using a regression approach. Top row: Cox 597 regression, bottom row: random survival forest. Left column: feature selection in a 5-fold cross-598 validation. Features were ranked according to the concordance index value for the univariate 599 model. Right column: Prediction results for the test set in a 5-fold cross-validation, depending 600 on the number of features.





### 601

602 Figure 6: Kaplan-Meier plot of metastasis-free survival for the whole cohort. The patients were 603 divided into high-risk and low-risk groups according to a Cox model constructed using the 604 feature selection and number for which the cross-validation accuracy was highest.

### Supplementary appendix 605

606 Supplementary Table 1. Summary of the correlation-based feature filtering.

607

608 Supplementary Table 2. Potential of the data to predict EFS (clinical variables). Fisher's ex-609 act test was applied for p-value estimation.

610

Supplementary Table 3. Potential of the data to predict MFS and EFS. For binary MFS and 611 612 EFS, the Mann-Whitney U test was used. For the continuous MFS log-rank test. Variables

613 statistically significant against continuous MFS are highlighted in bold.

- 614
- 615 Supplementary Table 4. Log-rank test for continuous MFS.

616 617 **Supplementary Figure 1.** Principal component analysis of the radiomic features (after corre-

618 lation filtering). Colors correspond to the PET/CT scanner. There is no visible grouping of 619 samples according to the scanner. 620

- 621 Supplementary Figure 2. Correlation between radiomic features.
- 622

- 623 Supplementary Figure 3. Kaplan-Meier plot for metastatic-free survival with high/low
- 624 SmallAreaLowGrayLevelEmphasis value
- 625
- 626 Supplementary Figure 4. Kaplan-Meier plot for metastatic-free survival with high/low Run-
- 627 LengthNonUniformity value

628